Dr. Mesa on Long-Term Data From the COMFORT Trials

Ruben A. Mesa, MD
Published: Monday, Mar 25, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Data from the COMFORT trials shows that most patients switched to ruxolitinib (from placebo or best alternative therapy). After the switch, patients saw benefits such as spleen size reduction and symptomatic improvement. These responses were durable as patients remained on ruxolitinib and experienced survival benefit.

Survival advantage was particularly noticeable in those who saw clear weight gain, reversible cachexia with the disease, and improvement in hypercholesterolemia.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Data from the COMFORT trials shows that most patients switched to ruxolitinib (from placebo or best alternative therapy). After the switch, patients saw benefits such as spleen size reduction and symptomatic improvement. These responses were durable as patients remained on ruxolitinib and experienced survival benefit.

Survival advantage was particularly noticeable in those who saw clear weight gain, reversible cachexia with the disease, and improvement in hypercholesterolemia.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x